U.S. Markets open in 3 hrs 39 mins

PRA Health Simplifies Treatment Decisions With Metys Launch

Zacks Equity Research

PRA Health Sciences, Inc. PRAH recently launched Symphony Health’s national market measurement tool, known as Metys, in an effort to enhance its position and capabilities in the data and analytics field. Notably, the new tool is the only integrated all-in-one market research solution that is available from a contract research organization (CRO).

It is important to note here that in September 2017, PRA Health completed the acquisition of Symphony Health — a provider of data and analytics that enable companies to get an idea of the full market lifecycle of products offered for sale in the pharmaceutical industry.

Few Words about Metys

Being the first platform of its kind, Metys delivers pharmaceutical market analytics and intelligence in a timely and comprehensive manner. The tool integrates prescriber, payer and patient data assets, along with source of business, managed care and other key metrics. This provides a complete picture of market activity with excellent speed and precision. Notably, Metys is the only national market measurement solution that includes linked diagnosis subgroups to projected prescriptions and writers.

PRA Health Sciences Set to Gain

With each passing day, complete understanding, measuring and influencing treatment decisions are becoming crucial. With this new tool, the company expects cater to its clients more efficiently, while reinforcing its culture of innovation and excellence.

PRA Health, like other CROs, derive substantially all of its revenues from the research, development and marketing expenditures of the pharmaceutical, biotechnology and medical device industries. With worldwide increase in demand for outsourced clinical development solutions, the CRO industry is gaining rapid traction and popularity.

Market Prospects

Per a report by Energias Market Research, the global life science analytics market is anticipated to grow substantially from $10.6 billion in 2017 to $25.2 billion in 2024, at a CAGR of 12.1% from 2018-2024. Technological advancements and availability of big data in life science industry are driving the market.

Zacks Rank and Price Performance

Currently, PRA Health carries a Zacks Rank #3 (Hold). Shares of PRA Health gained 13.5% year to date, against the industry’s decline of 10.8%. Meanwhile, the S&P 500 Index rallied 18.5% in the same time frame.



 

Key Picks

Some better-ranked stocks from the broader medical space are Baxter International Inc. BAX, Amedisys, Inc. AMED and CONMED Corporation CNMD, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Baxter has a long-term earnings growth rate of 12.8%.

Amedisys has a long-term earnings growth rate of 16.3%.

CONMED has a long-term earnings growth rate 14.9%.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Baxter International Inc. (BAX) : Free Stock Analysis Report
 
Amedisys, Inc. (AMED) : Free Stock Analysis Report
 
CONMED Corporation (CNMD) : Free Stock Analysis Report
 
PRA Health Sciences, Inc. (PRAH) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research